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ABSTRACT
Background. Lymph node (LN) yield in colon cancer
resection specimens is an important indicator of treatment
quality and has especially in early-stage patients therapeutic
implications. However, underlying disease mechanisms,
such as microsatellite instability (MSI), may also inﬂuence
LN yield, as MSI tumors are known to exhibit more promi-
nentlymphocyticantitumorreactions.Theaimofthepresent
study was to investigate the association of LN yield, MSI
status, and recurrence rate in colon cancer.
Methods. Clinicopathological data and tumor samples
were collected from 332 stage II and III colon cancer
patients. DNA was isolated and PCR-based MSI analysis
performed. LN yield was deﬁned as ‘‘high’’ when 10 or
more LNs were retrieved and ‘‘low’’ in case of fewer than
10 LNs.
Results. Tumors with high LN yield were signiﬁcantly
associated with the MSI phenotype (high LN yield: 26.3%
MSI tumors vs low LN yield: 15.1% MSI tumors;
P = .01), mainly in stage III disease. Stage II patients with
high LN yield had a lower recurrence rate compared with
those with low LN yield. Patients with MSI tumors tended
to develop fewer recurrences compared with those with
MSS tumors, mainly in stage II disease.
Conclusions. In the present study, high LN yield was
associated with MSI tumors, mainly in stage III patients.
Besides adequate surgery and pathology, high LN yield is
possibly a feature caused by biologic behavior of MSI
tumors.
Colorectal cancer (CRC) is the third most common form
of cancer and the second leading cause of cancer-related
death in the Western world, with more than 600,000 deaths
worldwide each year.
1
Currently, the tumor-node-metastasis (TNM) staging
system, developed by the American Joint Committee on
Cancer (AJCC) and the International Union Against Cancer
(UICC), is the primary method for assessing prognosis for
individual patients.
2
For patients with lymph node metastases (TNM stage
III), adjuvant chemotherapy after resection of the primary
tumor is recommended, because of high risk for disease
recurrence. Adjuvant 5-ﬂuorouracil (5-FU)-based chemo-
therapy has been found to increase median 5-year survival
in stage III colon cancer patients from 51% to 64%.
3
Moreover, combinations of 5-FU-based therapy with oxa-
liplatin have further improved response rates and disease-
free survival.
4 However, so far no convincing evidence
exists for a beneﬁcial effect of postoperative adjuvant
chemotherapy in patients without lymph node metastases
(TNM stage I and II), while 20%–30% of stage II patients
will still develop recurrent disease.
5,6 One of the dilemmas
here is the number of lymph nodes actually required for
making an accurate call of stage II colon cancer. In fact,
numbers ranging from as low as 4 to as high as 40 nodes
have been suggested for adequate staging.
7–18 Although
most current recommendations stick to a minimum number
of 10–12 lymph nodes to be investigated, in routine clinical
 The Author(s) 2011. This article is published with open access
at Springerlink.com
First Received: 10 March 2011;
Published Online: 12 October 2011
G. A. Meijer, MD, PhD
e-mail: ga.meijer@vumc.nl
Ann Surg Oncol (2012) 19:1222–1230
DOI 10.1245/s10434-011-2091-7practice this is certainly not always achieved.
19–21 Besides
its pivotal role in accurate staging, a high lymph node yield
has been associated with a better prognosis in both stage II
and III colon cancer, an observation for which no clear
biological explanation has been found.
9,12,15,18,22–25
Extent of surgical resection and thorough pathological
evaluation of the resection specimen play an important role
in the total number of lymph nodes identiﬁed. Moreover,
underlying disease mechanisms of colon cancer may have
an important effect on lymph node harvest as well. Possi-
bly, biological behavior of the tumor and interactions
between tumor and host affect characteristics of peritu-
moral lymph nodes resulting in improved node yield. One
of the underlying biological factors that has been suggested
to inﬂuence the number of lymph nodes retrieved in the
resection specimens is the microsatellite instability status
of colon cancer, which in itself is also associated with
clinical outcome.
26 The aim of the present study was to
investigate the association of lymph node yield, MSI status,
and recurrence rate in stage II and III colon cancer patients.
PATIENTS AND METHODS
From 1996 to 2005, a total of 667 patients underwent
surgical resection for colon cancer at the Kennemer Gast-
huis hospital in Haarlem, the Netherlands. Of these, 454
were classiﬁed as TNM stage II (T3–4, N0, M0) or III
(T1–4, N1–2, M0) according to the TNM staging system by
the AJCC and UICC.
27
Data were collected from clinical reports and included
date of birth, date of surgery, location of the primary
tumor, that is, right-sided (caecal, ascending, transverse) or
left-sided (descending, sigmoid, rectosigmoid), adjuvant
chemotherapy, date and site of ﬁrst disease recurrence, and
cause of death, that is, colon cancer related or unrelated
cause of death. Disease recurrence was deﬁned as either
local tumor recurrence or distant metastases, diagnosed by
computed tomography imaging and/or histopathology.
From the histopathology reports, information was
retrieved about tumor size, tumor and nodal stage, differ-
entiation grade, ulceration, mucinous differentiation, and
angioinvasion of the primary tumor. In line with the Dutch
national guidelines, lymph node (LN) yield was deﬁned as
‘‘high’’ when 10 or more LNs were retrieved and ‘‘low’’ in
case of fewer than 10 LNs.
Patients with a previous history of colorectal malig-
nancy (n = 12) and those with incomplete resections of the
primary tumor (macroscopically or microscopically,
n = 9) were excluded from this study. Also patients who
were lost for follow-up or died within 3 months after sur-
gery (n = 8 and n = 39, respectively) were excluded. Of
the 386 eligible patients, microsatellite instability status
could not be determined in 54 cases (see the section
‘‘Microsatellite Instability Analysis’’), which were also
excluded from this study.
The remaining study population consisted of 332 stage
II and III colon cancer patients: 181 males and 151 females
with a mean age of 70 years and a median follow-up period
of more than 57 months (Table 1). Adjuvant 5-FU-based
chemotherapy was administered to 15.7% of stage II
patients and 55.8% of stage III patients.
Lymph Node Retrieval and Examination
After resection of the colon, the specimens were placed
in formalin and allowed to ﬁx for at least 24 hours. After
proper ﬁxation, the mesenteric fat was cut into thin slices
and lymph nodes were sampled: small lymph nodes not
exceeding 5 mm in diameter were included in toto,
somewhat larger lymph nodes (diameter 5–10 mm) were
cut in half, and lymph nodes larger than 10 mm were sliced
in equal intervals and subsequently placed in marked cas-
settes. After conventional histological staining with
hematoxylin and eosin, the lymph nodes were microscop-
ically examined for the presence of metastases.
DNA Isolation
DNA was isolated from formalin-ﬁxed parafﬁn-embed-
ded (FFPE) colon cancer tissues samples. For each tumor,
areas with at least 70% tumor cells were selected from
4-lm sections. Adjacent serial sections of 10 lm were cut
and macrodissected. DNA was isolated as previously
described (using QIAamp microkit; Qiagen, Hilden, Ger-
many).
28 DNA concentrations were measured with a
Nanodrop-100 spectrophotometer (Isogen, De Meern, The
Netherlands).
Microsatellite Instability Analysis
Tumor samples were analyzed for microsatellite insta-
bility (MSI) using MSI Analysis System, Version 1.2
according to the manufacturer’s instructions (Promega,
Madison, WI). This PCR-based assay uses 5 mononucle-
otide repeat markers to determine MSI status. PCR
products were separated by capillary electrophoresis using
the ABI 3130 DNA sequencer, and output data were ana-
lyzed using the accompanying package GeneScan 3100
(Applied Biosystems, Foster City. CA). Tumors were
classiﬁed as microsatellite instable (MSI) when instability
was observed for 2 or more markers. When instability was
observed for none or only 1 marker, tumors were consid-
ered to be microsatellite stable (MSS). MSI status could be
determined in 332 cases, (i.e., 86% of tumor samples, while
Lymph Node Yield Related to MSI in Colon Cancer 1223attempts to characterize the remaining 14% failed because
of insufﬁcient quality of the FFPE-derived DNA material).
Statistical Analysis
Differences between sample means were determined
using the t test. Differences in proportions between groups
were examined using Pearson’s chi-square test. Survival
rates were displayed using the Kaplan-Meier method and
compared using the log-rank test. All reported P values are
2-sided, and a signiﬁcance level of .05 was used. Statistical
analysis was performed with SPSS 17.0 for Windows,
SPSS Inc., Chicago, IL.
RESULTS
Of the 185 stage II patients, 24.9% developed recurrent
disease, while for the 147 stage III patients this was 45.6%
TABLE 1 Clinical and pathological characteristics of study population
Overall (n = 332) LN\10 (n = 199) LN C 10 (n = 133) P value
Sex
Male 181 (54.5) 109 (54.8) 72 (54.1)
Female 151 (45.5) 90 (45.2) 61 (45.9) NS
Age (years)
Mean (s.d.) 70.6 (12.1) 71.4 (12.3) 69.5 (11.7)
Median (range) 72.8 (28.5–94.0) 73.4 (28.5–94.0) 71.9 (34.5–91.3) NS
Tumor location
Right sided 148 (44.6) 78 (39.2) 70 (52.6)
Left sided 184 (55.4) 121 (60.8) 63 (47.4) .02
Tumor size (mm), Mean (s.d) 42.4 (20.1) 40.4 (20.1) 45.4 (20.0) .03
Tumor stage
T1 4 (1.2) 3 (1.5) 1 (0.8)
T2 18 (5.4) 12 (6.0) 6 (4.5)
T3 277 (83.4) 160 (80.4) 117 (88.0)
T4 33 (9.9) 24 (12.1) 9 (6.8) NS
Microsatellite instability status
MSS 267 (80.4) 169 (84.9) 98 (73.7)
MSI 65 (19.6) 30 (15.1) 35 (26.3) .01
Histological differentiation grade
Poorly 48 (14.5) 28 (14.1) 20 (15.0)
Moderately/well 284 (85.5) 171 (85.9) 113 (80.0) NS
Mucinous differentiation
Yes 66 (19.9) 42 (21.1) 24 (18.0)
No 266 (80.1) 157 (78.9) 109 (82.0) NS
Ulceration
Present 258 (77.7) 150 (75.4) 108 (81.2)
Absent 74 (22.3) 49 (24.6) 25 (18.8) NS
Angioinvasion
Present 73 (22.0) 39 (19.6) 34 (25.6)
Absent 259 (78.0) 160 (80.4) 99 (74.4) NS
TNM stage
Stage II 185 (55.7) 118 (59.3) 67 (50.4)
Stage III 147 (44.3) 81 (40.7) 66 (49.6) NS
Recurrence
Yes 113 (34.0) 75 (37.7) 38 (28.6)
No 219 (66.0) 124 (62.3) 95 (71.4) .09
Follow up (months), median (range) 57.1 (3.5–148.6) 54.0 (4.3–142.6) 61.8 (3.5–148.6) .06
MSI microsatellite instable tumors, MSS microsatellite stable tumors, NS not signiﬁcant
Values in parentheses are percentages unless stated otherwise
1224 E. J. Th. Belt et al.(P\.01). An overview of disease recurrence rates is dis-
played in Table 2. No difference in mean lymph node
retrieval was observed over time and between involved
surgeons and pathologists (data not shown).
High LN yield was observed in 133 patients (40.1%) and
low lymph node yield (\10 LN) in 199 (59.9%) patients.
Overall, patients with high LN yield tended to have fewer
recurrences compared with patients with low LN yield
(28.6% vs 37.7%, P = .09). Considering only stage II
patients,therewasasigniﬁcantdifferenceinrecurrencerate,
namely,16.4%forpatientswithhighLN(11of67)yieldand
29.7% for patients with low LN yield (35 of 118; P = .05).
Disease-free survival curves are displayed in Fig. 1.
Tumors with high LN yield were signiﬁcantly larger and
were located more frequently right-sided compared with
tumors with low LN yield (mean 45.4 mm vs 40.4 mm,
respectively, P = .03; right-sided 60.8% vs 47.2%,
respectively, P = .02).
Tumors with high LN yield were signiﬁcantly associated
with the MSI phenotype, as 26.3% of these tumors were
TABLE 2 Disease recurrence rates in 332 stage II and III colon cancer patients
Stage II ? III recurrence rate
Total (n = 332) MSI (n = 65) MSS (n = 267) P value
Total (n = 332) 34.0% 24.6% (16/65) 36.3% (97/267) .07
LN\10 (n = 199) 37.7% 30.0% (9/30) 39.1% (66/169) NS
LN C 10 (n = 133) 28.6% 20.0% (7/35) 31.6% (31/98) NS
P value .09 NS NS
Stage II recurrence rate
Total (n = 185) MSI (n = 38) MSS (n = 147) P value
Total (n = 185) 24.9% 13.2% (5/38) 27.9% (41/147) .06
LN\10 (n = 118) 29.7% 18.2% (4/22) 32.3% (31/96) NS
LN C 10 (n = 67) 16.4% 6.3% (1/16) 19.6% (10/51) NS
P value .05 NS .10
Stage III recurrence rate
Total (n = 147) MSI (n = 27) MSS (n = 120) P value
Total (n = 147) 45.6% 40.7% (11/27) 46.7% (56/120) NS
LN\10 (n = 81) 49.4% 62.5% (5/8) 47.9% (35/73) NS
LN C 10 (n = 66) 40.9% 31.6% (6/19) 44.7% (21/47) NS
P value NS NS NS
MSI microsatellite instable tumors, MSS microsatellite stable tumors, NS not signiﬁcant
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FIG. 1 Disease-free survival
curves of colon cancer patients
with high (C 10) and low
(\10) lymph node (LN) yield
for (a) stage II and (b) stage III
patients
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(P = .01). The mean LN yield of resected MSI tumors was
10.1 compared with 8.6 for MSS tumors (P = .03;
Fig. 2a). This difference though, was mainly observed in
stage III patients (Fig. 2b, c). For this subgroup, the mean
LN yield for MSI tumors was 11.7, compared with 9.1 for
MSS tumors (P\.01).
MSI vs MSS Tumors
Of all tumors, 19.6% appeared to be MSI and 80.4%
MSS. Disease recurrence occurred in 24.6% of the patients
with MSI tumors, compared with 36.3% of the patients
with MSS tumors (P = .07). This difference was mainly
attributable to stage II patients, as in this group the recur-
rence rate was 13.2% for patients with MSI tumors and
27.9% in MSS cases (P = .06). For stage III patients,
recurrence rates were 40.7% for MSI tumors and 46.7% in
case of MSS tumors (P = .6). Disease-free survival curves
are depicted in Fig. 3.
MSI tumors revealed a poor histological differentiation
in 30.8% compared with only 10.5% in cases of MSS
tumors (P\.01). MSI tumors were located more often
right-sided, compared with MSS tumors (62.9% vs 24.6%,
respectively, P\.01) and were signiﬁcantly larger (mean
54.2 mm vs 39.6 mm, P\.01).
Within the patient population with MSI tumors, a trend
toward better disease-free survival was seen for those with
high LN yield compared with patients with low LN yield,
as shown in Fig. 4a. For patients with MSS tumors, a
similar trend was observed (Fig. 4b). When these analyses
were performed stratiﬁed for disease stage, no signiﬁcant
differences in survival between patients with high LN yield
and those with low LN yield were seen (data not shown).
Multivariate Analysis
Multivariate analysis included sex, age, disease stage,
MSI status, tumor location, tumor diameter, differentiation
grade, presence of mucinous differentiation, ulceration, and
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dent factor associated with high lymph node yield (odds
ratio 2.3, 95% conﬁdence interval 1.2–4.4).
DISCUSSION
In the present study, high LN yield in the resection
specimen was associated with improved disease-free sur-
vival. This was observed mainly in stage II patients, while
for stage III patients only a trend toward better survival was
seen in cases of high LN yield. Regarding stage II patients,
we identiﬁed high-risk patients based on NCCN criteria.
29
We analyzed T-stage, histologic grade, vascular invasion,
and number of lymph nodes sampled of all tumor speci-
mens. These characteristics are included in Table 1 and
Fig. 2. For these characteristics, no signiﬁcant difference
was observed between patients with low lymph node count
(\10) and those with high lymph node count (C10), as
shown in Table 1.
Several studies strongly conﬁrm the association between
high LN yield and improved survival in colorectal cancer
patients, both in stage II and III disease.
10,15,18,25,30,31
The causal factors for this association are subject of
debate. Stage migration has been postulated as a factor.
Patients with lower numbers of nodes analyzed could be
falsely designated as stage I or stage II, when the nodes
examined contain no metastases, while additional node
samples would have revealed tumor and thus stage III
would have been assigned.
Moreover, resection of lymph nodes itself may have a
therapeutic effect. For patients with positive lymph nodes,
a higher number of recovered nodes has been associated
with better survival.
15,25,31–33 This was not strongly
conﬁrmed by the present study as stage III patients with
high LN yield showed only a trend toward better disease-
free survival.
Several explanations have been postulated to explain
why some resection specimens of colon cancer have high
lymph node yields and others do not. It has been suggested
that a low number of nodes recovered in a specimen is a
reﬂection of inadequate surgical resection or pathological
examination.
34–36 Guidelines recommending a certain
minimum number of investigated lymph nodes are also
based on the assumption that increased effort by the sur-
geon and pathologist will lead to higher lymph node
counts. However, large studies that show inferior survival
in colon cancer patients with fewer lymph nodes demon-
strated that this relationship could not be explained by
factors such as extent of surgical resection and pathologic
processing.
30, 37 Moreover, the fact that most societies
nowadays recommend a minimum number of 10 to 12
lymph nodes to be investigated, and this is only achieved in
about one-third to one-half of the patients, also indicates
that other factors besides surgical and pathologic skills may
play a role in lymph node yield.
19–21 Alternatively, a low
number of nodes may not necessarily represent the quality
of care a patient has received and instead may be inﬂu-
enced by underlying biological characteristics of the
tumors.
One of the underlying biological factors that have been
suggested to be of inﬂuence is the microsatellite instability
status of colon cancer. Microsatellite instability is 1 of 2
major distinct colorectal oncogenic pathways, the other
being chromosomal instability.
38–40 Microsatellite insta-
bility is observed in about 15% of sporadic colorectal
cancers and is caused by a defect in the DNA mismatch
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FIG. 4 Disease-free survival
curves of microsatellite instable
(MSI) (a) and microsatellite
stable (MSS) (b) colon cancer
patients with high (C10) and
low (\10) lymph node (LN)
yield
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been associated with a better prognosis compared with
MSS tumors.
38,40,41 One of the factors involved here could
be the antitumor immune response, which differs between
MSI and MSS colorectal cancers. In general, the immune
system recognizes neoplasia poorly, but in MSI colon
cancer with inﬁltrating lymphocytes, it has been shown that
mechanisms of T-cell cytotoxicity are activated.
42
Truncated peptides produced by frameshift mutations
that are common in MSI cancers because of failing DNA
mismatch repair may be immunogenic and contribute to the
host immune response resulting in the migration of acti-
vated T-cells into the malignant epithelium of the
tumor.
43–50 Moreover, marked lymphocytic, so-called
‘‘Crohn’s-like’’ inﬁltrates are a hallmark of MSI colorectal
cancers.
51 Microscopically, hyperplastic changes are seen
in lymph nodes draining colorectal tumors exhibiting
prominent antitumor immune reactions, and these tumors
were found to have larger and more detectable lymph
nodes.
52, 53 These ﬁndings suggest a relation between MSI
status of the primary tumor and lymph node yield in the
resection specimen. This is supported by the present study,
as MSI tumors were signiﬁcantly associated with a high
number of lymph nodes harvested (Fig. 2a).
The association between MSI phenotype and high
lymph node yield as was observed in the present study has
been reported before in 2 smaller and more heterogeneous
study populations compared with the present one.
54,55 One
study consisted of 82 stage I (n = 27) and II (n = 55) both
colon (n = 52) and rectal (n = 30) cancers, the other was
based on 121 stage I–III colon cancers (12 stage I, 71 stage
II, and 38 stage III patients).
54,55 In the present study, rectal
cancers were excluded, because in general these tumors are
treated with preoperative (chemo)radiation therapy, which
is known to inﬂuence lymph node retrieval of the resection
specimen.
56–58 In both earlier studies, heterogeneous
patient populations were investigated and analysis did not
include, in contrast to the present study, stratiﬁcation for
disease stage, possibly because the relatively small sample
sizes would not allow for meaningful subgroup analysis.
The present study consisted of 185 stage II and 147
stage III colon cancer patients. This is the ﬁrst study
reporting a signiﬁcant association between MSI tumors and
high LN yield in stage III colon cancer. Interestingly, the
effect of MSI on lymph node yield was highest in stage III
cancer, that is, in those tumors in which metastatic spread
to regional lymph has already occurred. This could be
caused by an additional boost of the immune response due
to more intimate exposure of lymphoid tissue to tumor cells
than in stage II tumors.
In conclusion, the present study showed a strong asso-
ciation between MSI phenotype and high lymph node yield
in colon cancer, mainly so in stage III disease. The biology
of MSI colon cancers can provide explanations for this,
while at the same time contributing to a better prognosis.
Conversely, a less favorable outcome in patients with lower
lymph node yields would then not only be attributable to
understaging due to missed positive lymph nodes, but also
to tumor intrinsic factors.
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